January 21, 2009 - Patients in Japan stand to benefit from the approval of four innovative medicines - Tasigna for the treatment of a life-threatening form of leukemia, Xolair for severe asthma, Co-Dio [*] for high blood pressure, and Lucentis® for wet age-related macular degeneration (AMD), an eye disease that is a major cause of blindness in people over the age of 50 in Japan.
The details can be read here.
No comments:
Post a Comment